Abstract: A modified bacteriophage capable of infecting a plurality of different target bacteria, which bacteriophage includes a toxin gene encoding a toxin protein which is toxic to the target bacteria; wherein the bacteriophage is lytic; and wherein the bacteriophage expresses host range determinant proteins which have a plurality of bacterial host specificities.
Abstract: Provided is a modified bacteriophage capable of infecting a target bacterium, which bacteriophage includes an ?/? small acid-soluble spore protein (SASP) gene encoding a SASP which is toxic to the target bacterium, wherein the SASP gene is under the control of a constitutive promoter which is foreign to the bacteriophage and the SASP gene.
Type:
Grant
Filed:
September 12, 2018
Date of Patent:
January 24, 2023
Assignee:
PHICO THERAPEUTICS LTD.
Inventors:
Heather Fairhead, Adam Wilkinson, Sarah Holme, Katy Pitts, Alison Jackson
Abstract: Modified bacteriophage, uses thereof, and compositions containing the modified bacteriophage are described. The compositions are useful for human treatment and may treat various conditions, including bacterial infections.
Type:
Grant
Filed:
October 8, 2015
Date of Patent:
November 8, 2022
Assignee:
PHICO THERAPEUTICS LTD.
Inventors:
Heather Fairhead, Adam Wilkinson, Katy Pitts, Anne Barnard, Emmanuele Severi, Neil Anderson
Abstract: Modified bacteriophage and compositions containing the modified bacteriophage are described. Exemplary compositions are useful for human treatment and may treat various conditions, including bacterial infections.
Type:
Grant
Filed:
October 8, 2015
Date of Patent:
February 1, 2022
Assignee:
PHICO THERAPEUTICS LTD
Inventors:
Heather Fairhead, Adam Wilkinson, Emmanuele Severi, Neil Anderson, Katy Pitts, Anne Barnard
Abstract: A method for modifying the genome of a lytic target phage, uses of the method and products thereof are described. Compositions comprising such phage are also described. The compositions may be formulated as a medicament, which are useful for human treatment and may treat various conditions, including bacterial infections.
Type:
Grant
Filed:
October 8, 2015
Date of Patent:
March 23, 2021
Assignee:
PHICO THERAPEUTICS LTD
Inventors:
Heather Fairhead, Adam Wilkinson, Anne Barnard, Emmanuele Severi, Neil Anderson, Katy Pitts
Abstract: A method for producing one or more hybrid bacteriophage host range determinant (HRD) sequences, which comprises: (1) identifying at least two DNA sequences, each encoding an HRD in a series of regions in the DNA sequence, wherein the HRDs are different from one another, (2) incorporating each region into a vector in which each region is flanked by a recognition site of a restriction enzyme capable of cutting DNA at a specific cleavage site outside of the recognition sequence, so that the cleavage site of the restriction enzyme is situated at the boundary of each region, wherein the cleavage site sequences of the regions from an individual series are different from one another and wherein the cleavage site sequences at the boundaries of corresponding regions from different series are the same; (3) treating the vectors with a restriction enzyme capable of cutting DNA at a specific cleavage site outside of the recognition sequence so as to generate a mixture of the regions; and (4) treating the mixture of the re
Type:
Grant
Filed:
April 7, 2017
Date of Patent:
September 22, 2020
Assignee:
Phico Therapeutics Ltd
Inventors:
Heather Fairhead, Adam Wilkinson, Emmanuele Severi
Abstract: A modified bacteriophage capable of infecting a plurality of different target bacteria, which bacteriophage includes a toxin gene encoding a toxin protein which is toxic to the target bacteria; wherein the bacteriophage is lytic; and wherein the bacteriophage expresses host range determinant proteins which have a plurality of bacterial host specificities.
Abstract: Provided is a modified bacteriophage capable of infecting a target bacterium, which bacteriophage includes an ?/? small acid-soluble spore protein (SASP) gene encoding a SASP which is toxic to the target bacterium, wherein the SASP gene is under the control of a constitutive promoter which is foreign to the bacteriophage and the SASP gene.
Type:
Grant
Filed:
February 26, 2014
Date of Patent:
June 7, 2016
Assignee:
PHICO THERAPEUTICS LTD.
Inventors:
Heather Fairhead, Adam Wilkinson, Sarah Holme, Katy Pitts, Alison Jackson
Abstract: Provided is a modified bacteriophage capable of infecting a target bacterium, which bacteriophage includes an ?/? small acid-soluble spore protein (SASP) gene encoding a SASP which is toxic to the target bacterium, wherein the SASP gene is under the control of a constitutive promoter which is foreign to the bacteriophage and the SASP gene.
Type:
Application
Filed:
February 26, 2014
Publication date:
August 28, 2014
Applicant:
PHICO THERAPEUTICS LTD.
Inventors:
Heather Fairhead, Adam Wilkinson, Sarah Holme, Katy Pitts, Alison Jackson
Abstract: Provided is a modified bacteriophage capable of infecting a target bacterium, which bacteriophage includes an ?/? small acid-soluble spore protein (SASP) gene encoding a SASP which is toxic to the target bacterium, wherein the SASP gene is under the control of a constitutive promoter which is foreign to the bacteriophage and the SASP gene.
Type:
Grant
Filed:
August 6, 2008
Date of Patent:
April 15, 2014
Assignee:
Phico Therapeutics Ltd.
Inventors:
Heather Fairhead, Adam Wilkinson, Sarah Holme, Katy Pitts, Alison Jackson
Abstract: A method of inhibiting bacterial cell growth or of treating or inhibiting a bacterial infection in a subject by administering to the subject a therapeutically effective amount of a polynucleotide encoding a polypeptide having ?/? small acid-soluble spore protein (SASP) activity in a delivery system which targets a bacterial cell.